Etex Corp. inked a distribution deal with Stryker Corp. (NYSE:SYK) for a pair of its private-label bone graft substitute products.
The Cambridge, Mass.-based biomaterials firm signed a non-exclusive distribution deal for Stryker’s spine division to market and sell Etex’s Bio MatrX Structure and Bio MatrX Generate products. Both products incorporate Etex’s nanocrystalline calcium phosphate bone putty.
ETEX Corp. won 510(k) clearance from the Food & Drug Administration for its CarriGen bone graft substitute and wasted no time getting the product on the market.
The Cambridge, Mass.-based biotech firm said the nanocrystalline calcium phosphate bone void filler is available for immediate sale through its independent sales force, according to a press release.
ETEX Corp. inked a non-exclusive deal with an Indiana company to distribute a bone putty used in spinal fusion treatments.
OrthoPediatrics Corp. will sell the Cambridge, Mass.-based company’s nanocrystalline calcium phosphate into the pediatric market in the U.S. and Canada. The product is used in spinal fusion procedures to fill bone voids or skeletal defects "that are not intrinsic to the stability of the bone structure," according to a press release.